Publication:
Plasma levels, safety, and 60-week efficacy of a once-daily double-boosted protease inhibitor regimen of atazanavir, saquinavir, and ritonavir

Simple item page
dc.contributor.authorWeerawat Manosuthien_US
dc.contributor.authorSomnuek Sungkanuparphen_US
dc.contributor.authorKiat Ruxrungthamen_US
dc.contributor.authorWisit Prasithsirikulen_US
dc.contributor.authorChatiya Athichathanabadien_US
dc.contributor.authorWoraphot Tantisiriwaten_US
dc.contributor.authorChureeratana Bowonwatanuwongen_US
dc.contributor.authorNopphanath Chumpathaten_US
dc.contributor.authorAchara Chaovavanichen_US
dc.contributor.otherThailand Ministry of Public Healthen_US
dc.contributor.otherMahidol Universityen_US
dc.contributor.otherThe HIV Netherlands Australia Thailand Research Collaborationen_US
dc.contributor.otherSrinakharinwirot Universityen_US
dc.contributor.otherChonburi Regional Hospitalen_US
dc.date.accessioned2018-07-12T02:32:35Z
dc.date.available2018-07-12T02:32:35Z
dc.date.issued2008-01-01en_US
dc.identifier.citationJournal of Acquired Immune Deficiency Syndromes. Vol.47, No.1 (2008), 127-129en_US
dc.identifier.doi10.1097/QAI.0b013e318157b0daen_US
dc.identifier.issn15254135en_US
dc.identifier.other2-s2.0-39049117418en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/123456789/19384
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=39049117418&origin=inwarden_US
dc.subjectImmunology and Microbiologyen_US
dc.titlePlasma levels, safety, and 60-week efficacy of a once-daily double-boosted protease inhibitor regimen of atazanavir, saquinavir, and ritonaviren_US
dc.typeLetteren_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=39049117418&origin=inwarden_US

Files

Collections

Scopus 2006-2010